B
Bull
Bull · 25%AKRO
$54.72
シナリオ価格
$54.650
+0.098 (+0.18%)終値時点
Loading chart…
- High
- 54.825
- Open
- 54.520
- VWAP
- 54.62
- Vol
- 15.31M
- Mkt Cap
- 1.62B
- Low
- 54.370
- Amount
- 836.28M
- EV/EBITDA, TTM
- -8.60
Akero Therapeutics, Inc. is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including metabolic dysfunction-associated steatohepatitis (MASH). Efruxifermin (EFX), its lead product candidate for MASH, is being evaluated in three ongoing Phase 3 studies: SYNCHRONY Outcomes in patients with compensated cirrhosis (F4) due to MASH, SYNCHRONY Histology in patients with pre-cirrhotic (F2-F3 fibrosis) MASH, and SYNCHRONY Real-World in patients with MASH (F1-F4). The Phase 3 SYNCHRONY program builds on the results of two Phase 2b clinical trials, the HARMONY study in patients with pre-cirrhotic MASH and the SYMMETRY study in patients with compensated cirrhosis due to MASH. EFX is an analog of fibroblast growth factor 21 (FGF21), which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates and proteins throughout the body.
バリュエーション指標
The current forward P/E ratio for Akero Therapeutics Inc (AKRO) is -11.92, compared to its 5-year average forward P/E of -8.99.
Alphio AI Price Scenarios for AKRO
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding AKRO
イベントタイムライン
ニュース
7.011-20GlobenewswireHalper Sadeh LLC Urges Shareholders of SEE, AXTA, SEMR, and AKRO to Reach Out for Rights Consultation
7.011-18PRnewswireHalper Sadeh LLC Encourages WOW, AKRO, HFWA, BRY Shareholders to Contact the Firm to Discuss Their Rights
7.011-12PRnewswireHalper Sadeh LLC Encourages NIC, AKRO, BRNS Shareholders to Contact the Firm to Discuss Their Rights
7.011-07GlobenewswireHalper Sadeh LLC Urges Shareholders of JAMF, CADE, AKRO, and GES to Reach Out for Rights Consultation
8.511-06GlobenewswireBRODSKY & SMITH INVESTOR ALERT: Announcing Investigations into Qorvo, Inc. (Nasdaq – QRVO), First Foundation Inc. (NYSE – FFWM), Akero Therapeutics, Inc. (Nasdaq - AKRO), and CoreCard Corporation (NYSE - CCRD)
AKRO FAQ — answered by Alphio AI
Akero Therapeutics, Inc. is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including metabolic dysfunction-associated steatohepatitis (MASH). Efruxifermin (EFX), its lead product candidate for MASH, is being evaluated in three ongoing Phase 3 studies: SYNCHRONY Outcomes in patients with compensated cirrhosis (F4) due to MASH, SYNCHRONY Histology in patients with pre-cirrhotic (F2-F3 fibrosis) MASH, and SYNCHRONY Real-World in patients with MASH (F1-F4). The Phase 3 SYNCHRONY program builds on the results of two Phase 2b clinical trials, the HARMONY study in patients with pre-cirrhotic MASH and the SYMMETRY study in patients with compensated cirrhosis due to MASH. EFX is an analog of fibroblast growth factor 21 (FGF21), which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates and proteins throughout the body. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。